Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2006

01-09-2006 | Original Paper

Association Between ABO Blood Group and Fibrosis Severity in Chronic Hepatitis C Infection

Authors: Armelle Poujol-Robert, Pierre-Yves Boëlle, Dominique Wendum, Raoul Poupon, Annie Robert

Published in: Digestive Diseases and Sciences | Issue 9/2006

Login to get access

Abstract

The progression of fibrosis in hepatitis C virus (HCV) infection is a process in which genes interact with environmental factors. A “clotting process” is involved in fibrogenesis. ABO blood group distribution is associated with thrombotic disease, non-O blood group increasing the risk of venous thrombosis. The aim of the study was to investigate whether ABO blood type contributes to the severity of fibrosis. We studied blood group distribution in 346 French patients with HCV infection who underwent biopsies. The distribution of non-O blood group was 40%, 55%, 62%, 71%, and 73% for the F0, F1, F2, F3 and F4 fibrosis scores, respectively. Non-O blood group was associated with increased severity of fibrosis, even after adjustment on gender, age, duration of infection, and alcohol consumption (odds ratio 1.8, 95% confidence interval 1.0–2.9; P=.04). Non-O blood group is an independent risk factor for the progression of liver fibrosis in HCV infection.
Literature
2.
go back to reference Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ (2003) Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 52:404–409PubMedCrossRef Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ (2003) Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 52:404–409PubMedCrossRef
3.
go back to reference Poujol-Robert A, Rosmorduc O, Serfaty L, Coulet F, Poupon R, Robert A (2004) Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 99:527–531PubMedCrossRef Poujol-Robert A, Rosmorduc O, Serfaty L, Coulet F, Poupon R, Robert A (2004) Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 99:527–531PubMedCrossRef
4.
go back to reference Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H, Thursz M (2003) Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 52:1206–1210PubMedCrossRef Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H, Thursz M (2003) Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 52:1206–1210PubMedCrossRef
5.
go back to reference Poujol-Robert A, Boëlle PY, Poupon R, Robert A (2004) Activated protein C resistance (factor V Leiden) as a risk factor for cirrhosis in chronic hepatitis C patients. Hepatology 39:1174–1175PubMedCrossRef Poujol-Robert A, Boëlle PY, Poupon R, Robert A (2004) Activated protein C resistance (factor V Leiden) as a risk factor for cirrhosis in chronic hepatitis C patients. Hepatology 39:1174–1175PubMedCrossRef
6.
go back to reference Jick H, Slone D, Westerholm B, Inman WH, Vessey MP, Shapiro S, Lewis GP, Worcester J (1969) Venous thromboembolic disease and ABO blood group type. A cooperative study. Lancet 1:539–542PubMedCrossRef Jick H, Slone D, Westerholm B, Inman WH, Vessey MP, Shapiro S, Lewis GP, Worcester J (1969) Venous thromboembolic disease and ABO blood group type. A cooperative study. Lancet 1:539–542PubMedCrossRef
7.
go back to reference Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–154PubMedCrossRef Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–154PubMedCrossRef
8.
go back to reference Robert A, Aillaud MF, Eschwege V, Randrianjohany A, Scarabin Y, Juhan-Vague I (2000) ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb Haemostasis 83:630–631 Robert A, Aillaud MF, Eschwege V, Randrianjohany A, Scarabin Y, Juhan-Vague I (2000) ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb Haemostasis 83:630–631
9.
go back to reference The French Metavir Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15–20 The French Metavir Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15–20
10.
go back to reference Agresti A (1996) An introduction to categorical data analysis. John Wiley & Sons, New York Agresti A (1996) An introduction to categorical data analysis. John Wiley & Sons, New York
11.
go back to reference Harrell FE (2001) Regression modeling strategies. Springer, New York Harrell FE (2001) Regression modeling strategies. Springer, New York
12.
go back to reference Anstee QM, Wright M, Goldin R,et al. (2004) The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure. Hepatology 40;534A Anstee QM, Wright M, Goldin R,et al. (2004) The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure. Hepatology 40;534A
13.
go back to reference Marra F, Grandaliano G, Valente AJ, Abboud HE (1995) Thrombin stimulates proliferation of liver fat-storing cells and expression of monocytes chemotactic protein-1: potential role in liver injury. Hepatology 22:780–787PubMed Marra F, Grandaliano G, Valente AJ, Abboud HE (1995) Thrombin stimulates proliferation of liver fat-storing cells and expression of monocytes chemotactic protein-1: potential role in liver injury. Hepatology 22:780–787PubMed
14.
go back to reference Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G (1995) Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. Hepatology 21:1238–1247PubMed Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G (1995) Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. Hepatology 21:1238–1247PubMed
15.
go back to reference Goodman ZD, Ishak KG (1982) Occlusive venous lesions in alcoholic liver disease. Gastroenterology 83:786–796PubMed Goodman ZD, Ishak KG (1982) Occlusive venous lesions in alcoholic liver disease. Gastroenterology 83:786–796PubMed
16.
go back to reference Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691–1695PubMed Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691–1695PubMed
17.
go back to reference Kraaijenhagen RA, in’t Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Buller HR (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83:5–9PubMed Kraaijenhagen RA, in’t Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Buller HR (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83:5–9PubMed
18.
go back to reference Kamphuisen PW, Eikenboom JCJ, Bertina RM (2001) Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21:731–738PubMed Kamphuisen PW, Eikenboom JCJ, Bertina RM (2001) Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21:731–738PubMed
Metadata
Title
Association Between ABO Blood Group and Fibrosis Severity in Chronic Hepatitis C Infection
Authors
Armelle Poujol-Robert
Pierre-Yves Boëlle
Dominique Wendum
Raoul Poupon
Annie Robert
Publication date
01-09-2006
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9121-5

Other articles of this Issue 9/2006

Digestive Diseases and Sciences 9/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.